Literature DB >> 16343175

Radical hysterectomy for stage IIB cervical cancer: a review.

P Suprasert1, J Srisomboon, T Kasamatsu.   

Abstract

Patients with stage IIB cervical cancer in some countries in Europe and Asia especially in Japan are usually treated with radical hysterectomy and pelvic lymphadenectomy. Extrauterine diseases, ie, nodal metastases, parametrial invasion, and intraperitoneal spread, can be readily identified. We present the literature review of radical hysterectomy in stage IIB cervical cancer by searching data since 1980 from Medline, and we found that the parametrial involvement of patients in this stage was only 21-55%, the incidence of pelvic node metastases was about 35-45%, and 5-year survival rate was between 55% and 77%. Lymph node metastases and the number of positive nodes were significant prognostic factors of patients in this stage.

Entities:  

Mesh:

Year:  2005        PMID: 16343175     DOI: 10.1111/j.1525-1438.2005.00259.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  16 in total

1.  Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma.

Authors:  ShanShan Yang; Ying Gao; Jing Sun; Bairong Xia; TianBo Liu; HongXia Zhang; Qi Li; Min Xiao; YunYan Zhang
Journal:  Tumour Biol       Date:  2015-01-21

Review 2.  Progress in the Study of Lymph Node Metastasis in Early-stage Cervical Cancer.

Authors:  Bang-Xing Huang; Fang Fang
Journal:  Curr Med Sci       Date:  2018-08-20

3.  Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer.

Authors:  Koji Matsuo; Muneaki Shimada; Keiichiro Nakamura; Yuji Takei; Kimio Ushijima; Toshiyuki Sumi; Tatsuru Ohara; Hideaki Yahata; Mikio Mikami; Toru Sugiyama
Journal:  Eur J Surg Oncol       Date:  2019-02-18       Impact factor: 4.424

4.  Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy.

Authors:  Dae Woo Lee; Young Tae Kim; Jae Hoon Kim; Sunghoon Kim; Sang Wun Kim; Eun Ji Nam; Jae Wook Kim
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

Review 5.  Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence.

Authors:  Shinya Matsuzaki; Maximilian Klar; Mikio Mikami; Muneaki Shimada; Brendan H Grubbs; Keiichi Fujiwara; Lynda D Roman; Koji Matsuo
Journal:  Curr Oncol Rep       Date:  2020-02-12       Impact factor: 5.075

6.  Radiation-sparing managements for cervical cancer: a developing countries perspective.

Authors:  Myrna Candelaria; Lucely Cetina; Alicia Garcia-Arias; Carlos Lopez-Graniel; Jaime de la Garza; Elizabeth Robles; Alfonso Duenas-Gonzalez
Journal:  World J Surg Oncol       Date:  2006-11-13       Impact factor: 2.754

7.  Downregulation of HOTAIR Expression Mediated Anti-Metastatic Effect of Artesunate on Cervical Cancer by Inhibiting COX-2 Expression.

Authors:  Lixin Zhang; Hua Qian; Min Sha; Zhengyun Luan; Mei Lin; Donglan Yuan; Xiaokang Li; Junxing Huang; Lihua Ye
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

8.  Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix.

Authors:  T Kasamatsu; T Onda; M Sawada; T Kato; S Ikeda; Y Sasajima; H Tsuda
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640

9.  Radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer.

Authors:  Yanlan Chai; Tao Wang; Juan Wang; Yunyi Yang; Ying Gao; Jiyong Gao; Shangfeng Gao; Yueling Wang; Xi Zhou; Zi Liu
Journal:  BMC Cancer       Date:  2014-02-04       Impact factor: 4.430

10.  The influence of number of high risk factors on clinical outcomes in patients with early-stage cervical cancer after radical hysterectomy and adjuvant chemoradiation.

Authors:  Soyi Lim; Seok-Ho Lee; Kwang Beom Lee; Chan-Yong Park
Journal:  Obstet Gynecol Sci       Date:  2016-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.